X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NPX887 is a fully human monoclonal antibody targeting HHLA2 (B7-H7), a novel immune checkpoint and tumor target antigen. It is being evaluated for non-small cell lung cancer, renal cell carcinoma, colorectal carcinoma & other solid tumor types known to express HHLA2/B7-H7.
Lead Product(s): NPX887
Therapeutic Area: Oncology Product Name: NPX887
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
The funds aim to support the clinical development of NPX267 for the treatment of patients with metastatic solid tumors including (EGFR)-mutant non-small cell lung cancer and HHLA2 expressing metastatic malignant neoplasm.
Lead Product(s): NPX267
Therapeutic Area: Oncology Product Name: NPX267
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Catalio Capital Management
Deal Size: $122.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing February 14, 2024
Details:
NextPoint investigational product NPX887 is a fully human monoclonal antibody targeting HHLA2 (B7-H7). Currently evaluating under the IND enabling stage for the treatment of solid tumors known to express HHLA2, a tumor antigen strongly upregulated in many human cancers.
Lead Product(s): NPX887
Therapeutic Area: Oncology Product Name: NPX887
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2023
Details:
NPX267 is a first-in-class monoclonal antibody targeting KIR3DL3, the inhibitory receptor for the HHLA2 pathway (B7-H7), and is designed to prevent immune escape in solid tumors.
Lead Product(s): NPX267
Therapeutic Area: Oncology Product Name: NPX267
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2023
Details:
The financing will be used to advance NextPoint’s two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Leaps by Bayer
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 10, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
